[go: up one dir, main page]

AU2001263114A1 - Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci - Google Patents

Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Info

Publication number
AU2001263114A1
AU2001263114A1 AU2001263114A AU6311401A AU2001263114A1 AU 2001263114 A1 AU2001263114 A1 AU 2001263114A1 AU 2001263114 A AU2001263114 A AU 2001263114A AU 6311401 A AU6311401 A AU 6311401A AU 2001263114 A1 AU2001263114 A1 AU 2001263114A1
Authority
AU
Australia
Prior art keywords
taci
april
bcma
agp
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263114A
Inventor
Lars Eyde Theill
Gang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2001263114A1 publication Critical patent/AU2001263114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection. Disease states and disease parameters associated with APRIL and AGP-3 may be affected by modulation of BCMA or TACI; disease states and parameters associated with TACI can be affected by modulation of APRIL; disease states and parameters can be affected by modulation of any of TACI, BCMA, APRIL and AGP-3 by a single therapeutic agent or two or more therapeutic agents together.
AU2001263114A 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci Abandoned AU2001263114A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20403900P 2000-05-12 2000-05-12
US60204039 2000-05-12
USNOTGIVEN 2000-05-23
US21459100P 2000-06-27 2000-06-27
US60214591 2000-06-27
PCT/US2001/015567 WO2001087979A2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Publications (1)

Publication Number Publication Date
AU2001263114A1 true AU2001263114A1 (en) 2001-11-26

Family

ID=26899121

Family Applications (3)

Application Number Title Priority Date Filing Date
AU6155701A Pending AU6155701A (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001263114A Abandoned AU2001263114A1 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001261557A Ceased AU2001261557B2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU6155701A Pending AU6155701A (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001261557A Ceased AU2001261557B2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Country Status (10)

Country Link
US (2) US20020086018A1 (en)
EP (1) EP1280826B1 (en)
JP (1) JP2003533218A (en)
AT (1) ATE361318T1 (en)
AU (3) AU6155701A (en)
CA (1) CA2408617A1 (en)
DE (1) DE60128216T2 (en)
ES (1) ES2287130T3 (en)
MX (1) MXPA02011130A (en)
WO (2) WO2001087979A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
PT1255558E (en) * 2000-02-16 2006-11-30 Genentech Inc Anti-april antibodies and hybridoma cells
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
ATE451390T1 (en) * 2000-08-18 2009-12-15 Dyax Corp POLYPEPTIDES TO BIND TO B-LYMPHOCYTE-STIMULATORY PROTEIN (BLYS)
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
WO2002046231A2 (en) * 2000-12-07 2002-06-13 The University Of British Columbia Caml-binding peptides
WO2002066516A2 (en) * 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
JP2004537290A (en) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Antibodies to tumor necrosis factor δ (APRIL)
DK1436003T3 (en) * 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin fusion proteins
KR20040019105A (en) * 2001-08-03 2004-03-04 제넨테크, 인크. TACIs and BR3 Polypeptides and Uses Thereof
EP1456347A4 (en) * 2001-11-16 2006-08-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
DE60329116D1 (en) * 2002-10-11 2009-10-15 Zymogenetics Inc PREPARATION OF HOMOTRIMER FUSION PROTEINS
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050118728A1 (en) * 2003-07-02 2005-06-02 Caldwell Kevin K. Two-layer antibody capture system
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
AU2005305182A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind BAFF and/or APRIL
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
ZA200801354B (en) 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
EA015860B1 (en) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Methods for treatment of autoimmune diseases using neutrokine-alpha antagonist
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EA015342B1 (en) * 2006-05-15 2011-06-30 Арес Трейдинг С.А. Methods for treating autoimmune diseases using a taci-ig fusion molecule
BRPI0716139A2 (en) * 2006-08-28 2013-09-17 Ares Trading Sa fc fusion protein purification process
ES2755386T5 (en) * 2006-08-28 2023-04-05 Ares Trading Sa Process for the purification of proteins containing Fc fragments
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
CN105168123B (en) * 2007-11-12 2019-03-08 阿雷斯贸易股份有限公司 TACI-immunoglobulin fusion protein preparation
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
HUE027826T2 (en) * 2009-03-02 2016-11-28 Aduro Biotech Holdings Europe B V Antibodies against a proliferating inducing ligand (april)
MX353186B (en) 2009-09-03 2018-01-05 Genentech Inc Methods for treating, diagnosing, and monitoring rheumatoid arthritis.
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
JP6267512B2 (en) * 2010-09-10 2018-01-24 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． Stem cell culture medium and method
EP2640750A1 (en) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
CN103502472B (en) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 Biomarkers and methods for predicting response to B-cell antagonists
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CN106459990B (en) 2014-02-07 2021-06-01 麦克马斯特大学 Trifunctional T cell antigen conjugate and preparation method and use thereof
US20170247462A1 (en) 2014-07-03 2017-08-31 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN111234027A (en) 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
HRP20231578T1 (en) 2015-11-25 2024-03-15 Visterra, Inc. MOLECULES OF ANTIBODIES TO APRIL AND THEIR USES
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. CD3 BINDING ANTIBODIES
UA126384C2 (en) 2016-09-14 2022-09-28 Тенеобіо, Інк. AN ANTIBODY THAT BINDS CD3
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
AU2018289493B2 (en) 2017-06-20 2025-07-03 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
KR20250007003A (en) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 Anti-bcma heavy chain-only antibodies
WO2019046818A1 (en) * 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
UA129446C2 (en) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. TRISPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
TWI848951B (en) 2018-06-01 2024-07-21 瑞士商諾華公司 Binding molecules against bcma and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113710707B (en) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 Heavy chain antibody that binds to PSMA
BR112021023048A2 (en) 2019-05-21 2022-04-19 Novartis Ag cd19 binding molecules and uses thereof
CN119564852A (en) 2019-06-14 2025-03-07 特尼奥生物股份有限公司 Multispecific heavy chain antibodies that bind to CD22 and CD3
BR112022011964A2 (en) * 2019-12-17 2022-09-06 Shenzhen Feipeng Biological Therapy Co Ltd BCMA BINDING ANTIBODY AND USE THEREOF
CN115715220A (en) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 Multispecific heavy chain antibodies with modified heavy chain constant regions
CN115812077A (en) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
KR20240037892A (en) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. Claudin 18.2 T cell-antigen coupler and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
BR9612752A (en) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocin
WO1999035170A2 (en) 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
AU743490B2 (en) 1997-06-06 2002-01-24 Regeneron Pharmaceuticals, Inc. NTN-2 member of TNF ligand family
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EA005411B1 (en) 1997-09-12 2005-02-24 Апотек Р Энд Д Са Use antibody against april polypeptide for preparing medicament for treating tumors
EA200000311A1 (en) 1997-09-12 2000-10-30 Апотек Р Энд Д Са NEW PROTEIN IMMUNE SYSTEM - KAU
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
WO1999026976A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
IL136216A0 (en) 1997-12-03 2001-05-20 Genentech Inc Polypeptides and nucleic acids encoding the same
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE60005135T3 (en) * 1999-01-07 2015-04-09 Zymogenetics, Inc. SOLUBLE RECEPTORS BR43X2 AND METHOD FOR THEIR THERAPEUTIC USE
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1210425B2 (en) * 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
PT1255558E (en) * 2000-02-16 2006-11-30 Genentech Inc Anti-april antibodies and hybridoma cells

Also Published As

Publication number Publication date
AU2001261557B2 (en) 2005-06-30
AU6155701A (en) 2001-11-26
JP2003533218A (en) 2003-11-11
US20020086018A1 (en) 2002-07-04
CA2408617A1 (en) 2001-11-22
WO2001087979A3 (en) 2002-05-30
WO2001087977A3 (en) 2002-06-20
EP1280826A2 (en) 2003-02-05
ES2287130T3 (en) 2007-12-16
EP1280826B1 (en) 2007-05-02
US6774106B2 (en) 2004-08-10
MXPA02011130A (en) 2003-03-10
DE60128216D1 (en) 2007-06-14
WO2001087977A2 (en) 2001-11-22
US20020081296A1 (en) 2002-06-27
ATE361318T1 (en) 2007-05-15
DE60128216T2 (en) 2008-01-10
WO2001087979A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2001263114A1 (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
ZA201100893B (en) Inhibitors of bruton's tyrosine kinase
PL1742644T3 (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
ATE399553T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DEXTROMETHORPHAN AND QUINIDENE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
DK1407017T3 (en) Human receptor for tumor nekrose faktor
EP2172246A3 (en) Methods for Alzheimer's disease treatment and cognitive enhancement
DE60233720D1 (en) KAPPA OPIOID RECEPTOR LIGANDS
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
WO2005097219A3 (en) Ecm-based graft material
PT1053256E (en) Antibodies to death receptor 4 (dr4) and uses thereof
TW200735890A (en) Compositions and methods for increasing insulin sensitivity
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
ATE413179T1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL DEFICIENCY CONDITIONS
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE543491T1 (en) COMBINATION PREPARATION CONTAINING IBUPROFEN AND PARACETAMOL
EA200601288A1 (en) 1,3-DIPHENYLPROP-2-EN-1-SHE DERIVATIVES, METHOD OF THEIR RECEIVING AND APPLICATION
WO2000078327A3 (en) Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication
GB0102145D0 (en) Substances
MXPA02005069A (en) Tr3 specific binding agents and methods for their use.
SG179439A1 (en) Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
UA86802C2 (en) Combination of simethicone and bisacodyl for constipated patients suffering from bloated feeling
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor